BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 25175806)

  • 1. Drugging MYCN through an allosteric transition in Aurora kinase A.
    Gustafson WC; Meyerowitz JG; Nekritz EA; Chen J; Benes C; Charron E; Simonds EF; Seeger R; Matthay KK; Hertz NT; Eilers M; Shokat KM; Weiss WA
    Cancer Cell; 2014 Sep; 26(3):414-427. PubMed ID: 25175806
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual BRD4 and AURKA Inhibition Is Synergistic against MYCN-Amplified and Nonamplified Neuroblastoma.
    Felgenhauer J; Tomino L; Selich-Anderson J; Bopp E; Shah N
    Neoplasia; 2018 Oct; 20(10):965-974. PubMed ID: 30153557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PHA-680626 Is an Effective Inhibitor of the Interaction between Aurora-A and N-Myc.
    Boi D; Souvalidou F; Capelli D; Polverino F; Marini G; Montanari R; Pochetti G; Tramonti A; Contestabile R; Trisciuoglio D; Carpinelli P; Ascanelli C; Lindon C; De Leo A; Saviano M; Di Santo R; Costi R; Guarguaglini G; Paiardini A
    Int J Mol Sci; 2021 Dec; 22(23):. PubMed ID: 34884931
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BET inhibition silences expression of MYCN and BCL2 and induces cytotoxicity in neuroblastoma tumor models.
    Wyce A; Ganji G; Smitheman KN; Chung CW; Korenchuk S; Bai Y; Barbash O; Le B; Craggs PD; McCabe MT; Kennedy-Wilson KM; Sanchez LV; Gosmini RL; Parr N; McHugh CF; Dhanak D; Prinjha RK; Auger KR; Tummino PJ
    PLoS One; 2013; 8(8):e72967. PubMed ID: 24009722
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural basis of N-Myc binding by Aurora-A and its destabilization by kinase inhibitors.
    Richards MW; Burgess SG; Poon E; Carstensen A; Eilers M; Chesler L; Bayliss R
    Proc Natl Acad Sci U S A; 2016 Nov; 113(48):13726-13731. PubMed ID: 27837025
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The aurora kinase inhibitor CCT137690 downregulates MYCN and sensitizes MYCN-amplified neuroblastoma in vivo.
    Faisal A; Vaughan L; Bavetsias V; Sun C; Atrash B; Avery S; Jamin Y; Robinson SP; Workman P; Blagg J; Raynaud FI; Eccles SA; Chesler L; Linardopoulos S
    Mol Cancer Ther; 2011 Nov; 10(11):2115-23. PubMed ID: 21885865
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimization of ligand and lipophilic efficiency to identify an in vivo active furano-pyrimidine Aurora kinase inhibitor.
    Shiao HY; Coumar MS; Chang CW; Ke YY; Chi YH; Chu CY; Sun HY; Chen CH; Lin WH; Fung KS; Kuo PC; Huang CT; Chang KY; Lu CT; Hsu JT; Chen CT; Jiaang WT; Chao YS; Hsieh HP
    J Med Chem; 2013 Jul; 56(13):5247-60. PubMed ID: 23808327
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Small molecule inhibitors of aurora-a induce proteasomal degradation of N-myc in childhood neuroblastoma.
    Brockmann M; Poon E; Berry T; Carstensen A; Deubzer HE; Rycak L; Jamin Y; Thway K; Robinson SP; Roels F; Witt O; Fischer M; Chesler L; Eilers M
    Cancer Cell; 2013 Jul; 24(1):75-89. PubMed ID: 23792191
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting GD2 ganglioside and aurora A kinase as a dual strategy leading to cell death in cultures of human neuroblastoma cells.
    Horwacik I; Durbas M; Boratyn E; Węgrzyn P; Rokita H
    Cancer Lett; 2013 Dec; 341(2):248-64. PubMed ID: 23962557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery and Synthesis of a Pyrimidine-Based Aurora Kinase Inhibitor to Reduce Levels of MYC Oncoproteins.
    Chi YH; Yeh TK; Ke YY; Lin WH; Tsai CH; Wang WP; Chen YT; Su YC; Wang PC; Chen YF; Wu ZW; Yeh JY; Hung MC; Wu MH; Wang JY; Chen CP; Song JS; Shih C; Chen CT; Chang CP
    J Med Chem; 2021 Jun; 64(11):7312-7330. PubMed ID: 34009981
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A moving target: structure and disorder in pursuit of Myc inhibitors.
    Bayliss R; Burgess SG; Leen E; Richards MW
    Biochem Soc Trans; 2017 Jun; 45(3):709-717. PubMed ID: 28620032
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A MYC-aurora kinase A protein complex represents an actionable drug target in p53-altered liver cancer.
    Dauch D; Rudalska R; Cossa G; Nault JC; Kang TW; Wuestefeld T; Hohmeyer A; Imbeaud S; Yevsa T; Hoenicke L; Pantsar T; Bozko P; Malek NP; Longerich T; Laufer S; Poso A; Zucman-Rossi J; Eilers M; Zender L
    Nat Med; 2016 Jul; 22(7):744-53. PubMed ID: 27213815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TAS-119, a novel selective Aurora A and TRK inhibitor, exhibits antitumor efficacy in preclinical models with deregulated activation of the Myc, β-Catenin, and TRK pathways.
    Miura A; Sootome H; Fujita N; Suzuki T; Fukushima H; Mizuarai S; Masuko N; Ito K; Hashimoto A; Uto Y; Sugimoto T; Takahashi H; Mitsuya M; Hirai H
    Invest New Drugs; 2021 Jun; 39(3):724-735. PubMed ID: 33409897
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phosphorylation, Mg-ADP, and Inhibitors Differentially Shape the Conformational Dynamics of the A-Loop of Aurora-A.
    Musavizadeh Z; Grottesi A; Guarguaglini G; Paiardini A
    Biomolecules; 2021 Apr; 11(4):. PubMed ID: 33921540
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BPR1K653, a novel Aurora kinase inhibitor, exhibits potent anti-proliferative activity in MDR1 (P-gp170)-mediated multidrug-resistant cancer cells.
    Cheung CH; Lin WH; Hsu JT; Hour TC; Yeh TK; Ko S; Lien TW; Coumar MS; Liu JF; Lai WY; Shiao HY; Lee TR; Hsieh HP; Chang JY
    PLoS One; 2011; 6(8):e23485. PubMed ID: 21887256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sunitinib suppress neuroblastoma growth through degradation of MYCN and inhibition of angiogenesis.
    Calero R; Morchon E; Johnsen JI; Serrano R
    PLoS One; 2014; 9(4):e95628. PubMed ID: 24759734
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combination with crizotinib in ALK-mutated neuroblastoma.
    Moore NF; Azarova AM; Bhatnagar N; Ross KN; Drake LE; Frumm S; Liu QS; Christie AL; Sanda T; Chesler L; Kung AL; Gray NS; Stegmaier K; George RE
    Oncotarget; 2014 Sep; 5(18):8737-49. PubMed ID: 25228590
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting MYCN in neuroblastoma by BET bromodomain inhibition.
    Puissant A; Frumm SM; Alexe G; Bassil CF; Qi J; Chanthery YH; Nekritz EA; Zeid R; Gustafson WC; Greninger P; Garnett MJ; McDermott U; Benes CH; Kung AL; Weiss WA; Bradner JE; Stegmaier K
    Cancer Discov; 2013 Mar; 3(3):308-23. PubMed ID: 23430699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting of the MYCN protein with small molecule c-MYC inhibitors.
    Müller I; Larsson K; Frenzel A; Oliynyk G; Zirath H; Prochownik EV; Westwood NJ; Henriksson MA
    PLoS One; 2014; 9(5):e97285. PubMed ID: 24859015
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Switching Aurora-A kinase on and off at an allosteric site.
    Bayliss R; Burgess SG; McIntyre PJ
    FEBS J; 2017 Sep; 284(18):2947-2954. PubMed ID: 28342286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.